US Edition
Jacobson Pharma Announces FY2025 Annual Results – DIR HONGKONG
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Jacobson Pharma Announces FY2025 Annual Results – DIR HONGKONG
KEY HIGHLIGHTS – Revenue up by 7.4% to HK$1,576.9 million– Profit from continuing operations rose by 43.1% to HK$300.8 million– Net gearing ratio down to 8.3% from 12.2%– Recommended Final Cash Dividend of HK5.50 Cents Per Share and Special Cash Dividend of HK6.00 Cents Per Share– Continued enrichment of pipeline through R&D and strategic in-licensing– Improved operational efficiency by enhancing capacity and optimizing production leverage effic…
Results Highlights – Revenue increased by 7.4% to HK$1.58 billion – Profit from continuing operations increased by 43.1% to HK$300 million – Net gearing ratio decreased from 12.2% to 8.3% – Final cash dividend of 5.50 HK cents per share and special cash dividend of 6.00 HK cents per share are proposed – Product pipeline continues to be enriched through R&D and strategic in-licensing – Operational efficiency is promoted through improved operating…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
